Hologic, Inc. $HOLX Position Decreased by Candriam S.C.A.

Candriam S.C.A. decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 54.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 430,141 shares of the medical equipment provider’s stock after selling 514,191 shares during the period. Candriam S.C.A.’s holdings in Hologic were worth $26,570,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in HOLX. Zions Bancorporation National Association UT bought a new position in shares of Hologic during the 1st quarter valued at about $34,000. Allworth Financial LP lifted its stake in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Hologic during the first quarter valued at about $42,000. Larson Financial Group LLC lifted its stake in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 722 shares in the last quarter. Finally, Raiffeisen Bank International AG purchased a new stake in Hologic during the fourth quarter valued at about $49,000. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HOLX. Mizuho set a $75.00 price target on shares of Hologic in a research report on Thursday, July 31st. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 31st. Argus raised shares of Hologic from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a research report on Monday. Evercore ISI increased their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. Finally, Royal Bank Of Canada upgraded Hologic from a “sector perform” rating to an “outperform” rating and increased their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Hologic Trading Up 1.4%

Shares of HOLX stock opened at $68.76 on Thursday. The business’s 50 day moving average is $65.79 and its two-hundred day moving average is $62.55. The company has a market cap of $15.29 billion, a PE ratio of 28.53, a price-to-earnings-growth ratio of 2.46 and a beta of 0.49. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the company posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.